4.6 Review

RAS Dimers: The Novice Couple at the RAS-ERK Pathway Ball

Journal

GENES
Volume 12, Issue 10, Pages -

Publisher

MDPI
DOI: 10.3390/genes12101556

Keywords

RAS; dimerization; RAS signaling; cancer

Funding

  1. Spanish Ministry of Science (MICIU/AEI/FEDER, UE) [RTI2018-096658B-100]
  2. Asociacion Espanola Contra el Cancer (AECC) [GCB141423113]
  3. CIBERONC from the Instituto de Salud Carlos III (ISCIII) [IJCI-2017-32242]
  4. Juan de la Cierva program from the Spanish Ministry of Science (MICIU/AEI/FSE, UE) [IJCI-2017-32242]

Ask authors/readers for more resources

Signals transmitted through the RAS-ERK pathway play a crucial role in cancer-related cellular processes. RAS dimerization, especially at membrane microdomains, is essential for RAF activation and can be targeted pharmacologically to prevent tumorigenesis.
Signals conveyed through the RAS-ERK pathway constitute a pivotal regulatory element in cancer-related cellular processes. Recently, RAS dimerization has been proposed as a key step in the relay of RAS signals, critically contributing to RAF activation. RAS clustering at plasma membrane microdomains and endomembranes facilitates RAS dimerization in response to stimulation, promoting RAF dimerization and subsequent activation. Remarkably, inhibiting RAS dimerization forestalls tumorigenesis in cellular and animal models. Thus, the pharmacological disruption of RAS dimers has emerged as an additional target for cancer researchers in the quest for a means to curtail aberrant RAS activity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available